TABLE 2.
Baseline characteristics of patients with COVID-19 included in the meta-analysis.
| Baseline characteristics | Anti-IL-6 signaling group (N = 2,508) | SOC group (N = 5,015) | p value |
|---|---|---|---|
| Age, mean (±SD) (9 studies) | 61.78 ± 13.62 | 64.10 ± 16.13 | 0.0048 |
| Male, N (%) (32 studies) | 1809/2,488 (72.71%) | 3,121/4,990 (62.55%) | <0.0001 |
| Comorbidities, N (%) | |||
| Diabetes (29 studies) | 559/2,273 (24.59%) | 1,255/4,766 (26.33%) | 0.1258 |
| Hypertension (30 studies) | 848/2015 (42.08%) | 1,269/3,394 (37.39%) | 0.0007 |
| Heart diseases (10 studies) | 119/709 (16.78%) | 216/1,069 (20.21%) | 0.0727 |
| Coronary artery disease (15 studies) | 144/1,254 (11.48%) | 344/3,367 (10.22%) | 0.2333 |
| Obesity (7 studies) | 76/268 (28.36%) | 170/433 (39.26%) | 0.0034 |
| Lung diseases (6 studies) | 83/579 (14.34%) | 166/1,405 (11.81%) | 0.1359 |
| COPD (14 studies) | 95/1,008 (9.42%) | 189/2,452 (7.71%) | 0.1089 |
| Stroke (3 studies) | 9/165 (5.45%) | 15/225 (6.67%) | 0.6751 |
| Smoking (14 studies) | 196/1,000 (19.60%) | 440/2,545 (17.29%) | 0.1175 |
| CKD (13 studies) | 107/1,292 (8.28%) | 364/3,681 (9.89%) | 0.1006 |
N, number; SD, standard deviation; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.